SECAUCUS, N.J., Sept. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report.
The report provides information on the company's strategy regarding environmental, social, and governance (ESG) issues which aligns with The Quest Way, the company's purpose, strategy and culture.
"Our approach to ESG helps us to deliver on our strategy and our purpose of working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President.
"This report highlights our strategies and initiatives in equity and health access, employee and community engagement, governance, and the environment. Quest is well-positioned to play an even more significant role in the evolving healthcare ecosystem, including through our investments in the areas of molecular genomics, oncology and consumer health. I'm proud of the work our team is doing to help create a healthier world, and excited about what lies ahead for us."
In 2022, Quest took an important step in its ESG strategy, establishing a set of goals based on priorities identified in its materiality assessment. The four pillars of the company's ESG strategy are: Governance and ethics; Equity and health access; Employee and community engagement; and Environmental sustainability.
"We're making good progress executing our ESG strategy, driving alignment, and embedding ESG throughout our operations to build long-term sustainable value for all of our stakeholders," said Sam Samad, Executive Vice President and Chief Financial Officer, who leads the company's ESG Leadership Council. "Realizing our purpose of helping to create a healthier world requires a team effort among our employees, partners and the communities we serve."
The report features key impact areas and highlights from 2022, including:
Click here to view the report on the Quest Diagnostics corporate website.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Last Trade: | US$183.74 |
Daily Change: | -0.90 -0.49 |
Daily Volume: | 53,946 |
Market Cap: | US$20.550B |
October 21, 2025 September 23, 2025 September 18, 2025 September 04, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load